MUC1 and non-small cell lung carcinoma: Quoix et al. developed a viral vaccine (TG4010), a recombinant viral vaccine targeting MUC1, which significantly improves the survival rate of non-small cell lung cancer (NSCLC) patients with TG4010 treatment [195].